Learn languages naturally with fresh, real content!

Popular Topics
Explore By Region
Capricor Therapeutics' stock surged 500% after its Duchenne muscular dystrophy drug met key trial goals, reversing an earlier FDA rejection.
Capricor Therapeutics' stock soared up to 500% after its Phase 3 HOPE-3 trial for Deramiocel, a cell therapy for Duchenne muscular dystrophy, met its primary and secondary endpoints, showing significant improvement in heart function.
The positive results reversed a previous setback when the FDA rejected its approval application in July 2024.
The company immediately launched a public equity offering to leverage the renewed investor confidence.
Meanwhile, NEXTDC signed a deal with OpenAI to build a hyperscale AI campus in Sydney, boosting its shares 8% amid optimism over Australia’s sovereign AI infrastructure.
In mining, Critical Resources advanced its Cap Burn and Amoco projects in New Zealand and Australia, with promising drill results and plans for expanded exploration.
Las acciones de Capricor Therapeutics aumentaron un 500% después de que su fármaco para la distrofia muscular de Duchenne cumpliera los objetivos clave de los ensayos, revirtiendo un rechazo anterior de la FDA.